TG Therapeutics, Inc. (TGTX) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin 72.6%, revenue growth 70.3% YoY, P/E 18.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $616.29M |
| Revenue (TTM) | $0.8B |
| Net Margin | 72.6% |
| Return on Equity | 73.1% |
| Operating Margin (TTM) | 17.1% |
| Debt / Equity | 1.23 |
| Current Ratio | 4.27 |
| Net Debt / EBITDA | 1.9 |
| Interest Coverage | 3.6 |
| Revenue Growth (YoY) | 70.3% |
| EPS Growth (YoY) | -73.7% |
| FCF Growth (YoY) | 427.0% |
| P/E Ratio | 18.7 |
| EV / EBITDA | 62.4 |
| Price / Book | 13.66 |
| Price / Sales | 10.32 |
| FCF Yield | 0.2% |
| Altman Z-Score | 12.51 (safe) |
| Piotroski F-Score | 4/9 |
| Piotroski checks passed | 4 of 9 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
TGTX overview · TGTX earnings · TGTX KPIs · TGTX documents · TGTX ownership · TGTX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.